Have a feature idea you'd love to see implemented?
Let us know!
ADIL Adial Pharmaceuticals Inc
Price (delayed)
$1.1
Market cap
$7.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.7
Enterprise value
$3.76M
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist,
Highlights
Adial Pharmaceuticals's quick ratio has surged by 85% YoY but it has decreased by 45% QoQ
The company's EPS fell by 49% QoQ but it rose by 38% YoY
Adial Pharmaceuticals's net income has plunged by 57% YoY and by 41% from the previous quarter
Key stats
What are the main financial stats of ADIL
Market
Valuations
Earnings
Shares outstanding
6.4M
Market cap
$7.04M
Enterprise value
$3.76M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.09
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$12.24M
EBITDA
-$12.24M
Free cash flow
-$6.39M
Per share
Balance sheet
Liquidity
EPS
-$4.7
Free cash flow per share
-$1.53
Book value per share
$1.01
Revenue per share
$0
TBVPS
$1.18
Total assets
$4.95M
Total liabilities
$671,882
Debt
$0
Equity
$4.28M
Working capital
$3.15M
Debt to equity
0
Current ratio
5.69
Quick ratio
4.89
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-254.5%
Return on equity
-291.1%
Return on invested capital
-915.2%
Return on capital employed
-286.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADIL stock price
How has the Adial Pharmaceuticals stock price performed over time
Intraday
2.8%
1 week
13.39%
1 month
4.76%
1 year
-47.62%
YTD
-40.86%
QTD
10.11%
Financial performance
How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.27M
Net income
-$12.24M
Gross margin
N/A
Net margin
N/A
Adial Pharmaceuticals's net income has plunged by 57% YoY and by 41% from the previous quarter
The operating income rose by 18% year-on-year but it has declined by 13% since the previous quarter
Growth
What is Adial Pharmaceuticals's growth rate over time
Valuation
What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.09
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 49% QoQ but it rose by 38% YoY
The stock's price to book (P/B) is 76% less than its 5-year quarterly average of 4.6 but 21% more than its last 4 quarters average of 0.9
ADIL's equity is down by 30% QoQ but it is up by 29% YoY
Efficiency
How efficient is Adial Pharmaceuticals business performance
ADIL's return on assets has dropped by 73% year-on-year and by 32% since the previous quarter
The ROIC has shrunk by 70% QoQ but it rose by 30% YoY
ADIL's ROE is down by 33% QoQ and by 26% YoY
Dividends
What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADIL.
Financial health
How did Adial Pharmaceuticals financials performed over time
Adial Pharmaceuticals's quick ratio has surged by 85% YoY but it has decreased by 45% QoQ
Adial Pharmaceuticals's total liabilities has increased by 46% YoY and by 19% from the previous quarter
Adial Pharmaceuticals's debt is 100% less than its equity
ADIL's equity is down by 30% QoQ but it is up by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.